Skip to main navigation Press Releases Overview Press Releases Events & Presentations Corporate Governance SEC Filings Stock Information Investor Resources Year None 2021 2020 2019 Nov 29, 2021 Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer BOSTON --(BUSINESS WIRE)--Nov. 29, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Charmaine Lykins as PDF Version Nov 09, 2021 Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million , up to $152 million in potential near- and long-term development and commercial milestones and other payments, and low-double-digit to high-teens tiered PDF Version Nov 08, 2021 Karuna Therapeutics to Present at Upcoming Investor Conferences BOSTON --(BUSINESS WIRE)--Nov. 8, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate PDF Version Nov 04, 2021 Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively On track to initiate the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who inadequately respond to current standard of care in the fourth quarter of PDF Version Sep 01, 2021 Karuna Therapeutics to Present at 2021 Virtual Wells Fargo Healthcare Conference BOSTON --(BUSINESS WIRE)--Sep. 1, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate PDF Version Aug 31, 2021 Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference BOSTON --(BUSINESS WIRE)--Aug. 31, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul , M.D., chief PDF Version Aug 05, 2021 Karuna Therapeutics Reports Second Quarter 2021 Financial Results and Provides General Business Update All Phase 3 trials in the EMERGENT clinical program evaluating KarXT for the treatment of psychosis in adults with schizophrenia are enrolling Topline data from the Phase 3 EMERGENT-2 trial expected mid-2022 On track to initiate the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia PDF Version Aug 03, 2021 Karuna Therapeutics to Present at 2021 Wedbush PacGrow Healthcare Virtual Conference BOSTON --(BUSINESS WIRE)--Aug. 3, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul , M.D., chief executive PDF Version Jun 23, 2021 Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers Company to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022 Results suggest that KarXT can be administered to elderly volunteers at doses which achieve xanomeline blood levels similar to those reported in the Phase 2 EMERGENT-1 trial in adults with PDF Version Jun 02, 2021 Karuna Therapeutics to Present at Upcoming Investor Conferences BOSTON --(BUSINESS WIRE)--Jun. 2, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at PDF Version Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 21 Print Page Email Page RSS Feeds Email Alerts © 2021 Karuna Therapeutics™. All Rights Reserved. Privacy Policy. Terms of Use. Our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions About The Unmet Need Programs Careers Investors & Media Contact Top We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit:About Cookies Cookie Settings Accept